Novo Nordisk seeks new, "disruptive" options to escape US market pressure - CMO tells TPL

2 October 2018

At EASD 2018, The Pharma Letter spoke with Novo Nordisk’s (NOV: N) chief medical officer Stephen Gough and chief science officer Mads Krogsgaard Thomsen about recent job losses at the company, and the seismic potential of oral semaglutide.

The annual meeting of the European Association for the Study of Diabetes (EASD) is Europe’s premiere scientific conference for the therapy area.

For Dr Thomsen, the most exciting subject at the event is: "all the things that are happening in the GLP1 area," including data showing cardiovascular protection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK